Core Insights - Avidity Biosciences, trading as RNA on NASDAQ, is focused on RNA therapies and has a price target of $72 set by Roth Capital, indicating a potential increase of approximately 46.49% from its current price of $49.15 [1][5] - Novartis announced its acquisition of Avidity Biosciences for $12 billion, offering $72 per share, which has led to a 42% surge in RNA's stock price during premarket trading, highlighting the growing interest of Big Pharma in RNA therapies [2][5] - Despite the acquisition announcement, Novartis shares fell by 1%, indicating market reactions to the deal and reflecting Novartis's strategic move to enhance its biotech portfolio amid increasing generic competition [3][5] Company Performance - RNA's stock price fluctuated between $48.80 and $50.23 on the day of the acquisition announcement, with a yearly range from a low of $21.51 to a high of $56, and a current market capitalization of approximately $6.32 billion [4] - The trading volume for RNA was reported at 1,269,675 shares, indicating significant market activity following the acquisition news [4]

Core Viewpoint - Tango Therapeutics, Inc. (TNGX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance and Outlook - The upgrade reflects an improvement in Tango Therapeutics' underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - For the fiscal year ending December 2025, Tango Therapeutics is expected to earn -$1.05 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 23.3% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - The upgrade to Zacks Rank 2 places Tango Therapeutics in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Intellia Therapeutics experienced a significant stock drop of over 45%, closing at $13.90, following the suspension of two Phase 3 clinical trials related to its drug nex-z due to safety concerns [1] Group 1: Clinical Trials - The company has paused patient dosing and screening for two Phase 3 trials targeting patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy [1] - The suspension was prompted by a report of a patient experiencing grade 4 liver transaminase elevation and increased total bilirubin after treatment [1] - The affected patient has been hospitalized and is receiving medical intervention [1] Group 2: Company Response - Intellia is consulting with experts and considering potential risk mitigation strategies [1] - The company is also in communication with regulatory agencies, aiming to resume trial recruitment as soon as appropriate [1]

Sergey Brin’s name doesn’t appear in MapLight Therapeutics’ filings to go public, but the Google co-founder’s philanthropic ambitions could get a big boost from the biotech’s upcoming market debut https://t.co/pt8KuxTS1h ...

Earnings are just around the corner for IREN Limited (NASDAQ: IREN ), and with analysts projecting quite a bit of growth, I thought it would be useful to break down the full portfolio ofI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behi ...

Core Insights - Longeveron Inc. is advancing its clinical-stage cellular therapy, laromestrocel, aimed at treating hypoplastic left heart syndrome (HLHS), a severe congenital heart defect [1][2][4] - The pivotal Phase 2b clinical trial, ELPIS II, has completed enrollment, with top-line results expected in Q3 2026 [2][7] - Laromestrocel has shown promising results in previous trials, achieving 100% transplant-free survival up to five years of age compared to a historical mortality rate of approximately 20% [4] Company Overview - Longeveron Inc. focuses on developing regenerative medicines for unmet medical needs, with laromestrocel as its lead investigational product [5] - The company is pursuing multiple indications, including HLHS, Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [5] - Laromestrocel has received several FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, and RMAT designation for Alzheimer's disease [5] Clinical Trial Details - ELPIS II is a pivotal trial conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) and supported by NIH grants [4] - The trial aims to evaluate laromestrocel's efficacy as an adjunct treatment for HLHS, a rare pediatric disease [7] - The FDA has confirmed that successful results from ELPIS II could lead to a Biologics License Application (BLA) submission for full approval [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Click Holdings Limited (CLIK) is up 81% at $11.17 [3] - Avidity Biosciences, Inc. (RNA) is up 43% at $70.72 [3] - Dyne Therapeutics, Inc. (DYN) is up 37% at $23.58 [3] - Zenas BioPharma, Inc. (ZBIO) is up 21% at $29.00 [3] - ProPetro Holding Corp. (PUMP) is up 18% at $7.47 [3] - PepGen Inc. (PEPG) is up 17% at $5.35 [3] - Unusual Machines, Inc. (UMAC) is up 15% at $14.85 [3] - Semler Scientific, Inc. (SMLR) is up 14% at $27.32 [3] - ETHZilla Corporation (ETHZ) is up 13% at $20.51 [3] - Relmada Therapeutics, Inc. (RLMD) is up 13% at $2.38 [3] Premarket Losers - Smart Logistics Global Limited (SLGB) is down 37% at $3.21 [4] - MaxsMaking Inc. (MAMK) is down 22% at $4.08 [4] - Prenetics Global Limited (PRE) is down 14% at $14.40 [4] - United States Antimony Corporation (UAMY) is down 14% at $10.22 [4] - NeurAxis, Inc. (NRXS) is down 12% at $3.01 [4] - Obook Holdings Inc. (OWLS) is down 9% at $11.39 [4] - Qualigen Therapeutics, Inc. (QLGN) is down 9% at $3.30 [4] - Critical Metals Corp. (CRML) is down 8% at $13.70 [4] - Neuphoria Therapeutics Inc. (NEUP) is down 8% at $5.73 [4] - Beam Therapeutics Inc. (BEAM) is down 7% at $25.86 [4]

Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 27, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Insights - Creative Medical Technology Holdings, Inc. has made significant advancements in 2025, transitioning from proof-of-concept to clinical trials for regenerative stem cell therapies across multiple indications [1][2] - The company is leveraging proprietary cellular platforms, including AlloStem™, ImmCelz™, and iPScelz™, to position itself as a leader in regenerative medicine, capitalizing on breakthroughs in biology and AI [2][3] - Creative Medical's diversified platform strategy allows for multiple therapeutic approaches, enhancing market reach and reducing development risks [3][4] Clinical Trials - The company is advancing two pivotal FDA-cleared clinical programs targeting multi-billion-dollar markets, which are expected to serve as major near-term catalysts [5][6] - The trials utilize the AlloStem foundation, maximizing cost efficiency and scalability [6] Intellectual Property - Creative Medical boasts a strong intellectual property portfolio with over 60 patents and pending applications, including two cornerstone U.S. patents secured in Q3 2025 for ImmCelz, covering Type 1 Diabetes and Heart Failure [7] - These patents validate the company's core science and provide long-term exclusivity in high-value healthcare markets [7] AI Integration - The integration of AI into the iPScelz platform represents a significant advancement in regenerative medicine, aimed at accelerating target discovery and optimizing donor cell selection [8] - By utilizing AI to decode cellular behavior, the company is pioneering personalized regenerative medicine, enhancing treatment precision [9] Financial Strategy - The company operates with financial discipline, focusing investments on high-return milestones while maintaining a lean operational structure [9] - Multiple potential value-driving events are anticipated in the next 12 months, with a commitment to sustainable growth without excessive dilution [9] Future Focus - Creative Medical is dedicated to redefining possibilities in regenerative medicine, with validated science, scalable platforms, and a clear vision for long-term shareholder value [10]

Core Insights - Cocrystal Pharma has received a $500,000 SBIR Phase I award from NIH to develop a novel oral broad-spectrum antiviral for influenza A and B [1][2] - The funding will support the characterization of lead candidate molecules targeting the influenza polymerase complex [1] - Successful completion of Phase I may lead to eligibility for a larger Phase II award for further development [2] Company Overview - Cocrystal Pharma is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics targeting various viruses, including influenza and coronaviruses [6] - The company utilizes a structure-based drug discovery platform that provides insights for developing novel antiviral agents [5] Industry Context - Influenza poses a significant global health threat, with approximately 1 billion cases and up to 650,000 deaths annually [4] - The economic impact of influenza in the U.S. is estimated at $11.2 billion in direct and indirect costs each year [4]